Literature DB >> 368882

Thrombolytic therapy is arterial thromboembolism.

M Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 368882     DOI： 10.1016/0033-0620(79)90008-2

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN： 0033-0620            Impact factor:   8.194


× No keyword cloud information.
  9 in total

1.  Fibrinolytic therapy in peripheral arterial grafts utilizing the "crossed two catheter" technique.

Authors:  J Shewchun; K W Sniderman
Journal:  Cardiovasc Intervent Radiol       Date:  1989 Mar-Apr       Impact factor: 2.740

2.  Local thrombolysis in femoropopliteal occlusion: early and late results.

Authors:  G E Wilms; R H Verhaeghe; M M Pouillon; D Dewaele; A L Baert; J Vermylen; M Verstraete
Journal:  Cardiovasc Intervent Radiol       Date:  1987       Impact factor: 2.740

3.  Current therapy for intermittent claudication.

Authors:  M Verstraete
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

4.  Transcatheter thrombolysis in cancer patients.

Authors:  S Kudo; V P Chuang; S Wallace; S Mir; W Bechtel; C H Carrasco
Journal:  Cardiovasc Intervent Radiol       Date:  1985       Impact factor: 2.740

Review 5.  Coagulative interventions during angiography.

Authors:  J J Bookstein; K M Moser; C Hougie
Journal:  Cardiovasc Intervent Radiol       Date:  1982       Impact factor: 2.740

6.  Local infusion of low-dose streptokinase for renal artery thromboembolism.

Authors:  R F Gagnon; F Horosko; M J Herba
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

7.  Venous gangrene of the upper extremity.

Authors:  B M Smith; G W Shield; D H Riddell; J D Snell
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

Review 8.  Thrombolysis in thromboembolic diseases.

Authors:  D C Gulba; R Dechend
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 9.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.